MEK2 Antibody, anti-human, REAfinity™
Synonyms: MAP2K2, CFC4, MAPKK 2, MKK2, PRKMK2, MEK 2, MAPK/ERK kinase 2
RECOMBINANT
Clone:
REA449 | 96/MEK2
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for MEK2 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-822, 130-106-866
Description:
Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-MEK2 antibodies or with the corresponding REA Control (I) antibodies (left image) as well as with CD3 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Specifications for MEK2 Antibody, anti-human, REAfinity™
Overview

Clone REA449 recognizes the human MEK2 antigen regardless of phosphorylation status. MEK2 is a serine/threonine kinase also known as MAP kinase kinase (MAPKK 2) or MAPK/ERK kinase 2. The dual specificity kinases MEK1 and MEK2 are activated by RAF and mediate phosphorylation of ERK1 and ERK2. MEK1 and MEK2 are very similar but differ structurally in a proline-rich domain in the C-terminal half of the catalytic core. Binding of extracellular ligands such as growth factors, cytokines, and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival, and differentiation, predominantly through the regulation of transcription, metabolism, and cytoskeletal rearrangements.

Additional information: Clone REA449 displays negligible binding to Fc receptors.

Alternative names

MAP2K2, CFC4, MAPKK 2, MKK2, PRKMK2, MEK 2, MAPK/ERK kinase 2

Detailed product information

Technical specifications

Clone
REA449
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, rat, other
Cross-reactivity
mouse, rat, dog, chicken, frog
Antigen
MEK2
Molecular mass of antigen [kDa]
44
Entrez Gene ID
RRID
AB_2652850, AB_2652848, AB_2652851, AB_2652849

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for MEK2 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for MEK2 Antibody, anti-human, REAfinity™
Publications
  1. Kocieniewski, P. et al. (2013) MEK1 and MEK2 differentially control the duration and amplitude of the ERK cascade response. Phys. Biol. 10 (3): 035006-035006
  2. Ohren, J. F. et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11 (12): 1192-1197
  3. Zheng, C. F. et al. (1993) Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem. 268 (15): 11435-11439